A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire

Opioid-Related Disorders Clinical Trial

— POMAQ  

Official title:

A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02660606
• Other study ID #: Observational Study 3033-3
• Secondary ID: 3033-3
• Status: Completed
• Start date: January 2, 2015
• Est. completion date: January 18, 2016

Study information

• Verified date: April 2020
• Source: Member Companies of the Opioid PMR Consortium
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the patient usability and reliability of the POMAQ survey to evaluate opioid misuse and abuse among adults with chronic moderate to severe pain, including patients who are opioid abusers, non-abusers, as well as non-opioid users

Description:

The Food and Drug Administration (FDA) has requested, as part of a post-marketing requirement (PMR) for new drug application (NDA) holders of extended release/long-acting (ER/LA) opioids, to conduct a study to develop and validate a measure of the opioid-related adverse events misuse and abuse among patients with chronic pain prescribed long-term opioid therapy. This measure will be used to assess misuse and abuse in PMR Study 2065-1A and PMR Study 2065-4B.

Currently, no tool exists to meet this need except for the Self-report Misuse, Abuse and Diversion of Prescription (Rx) Opioids questionnaire (SR-MAD) which has undergone several rounds of prior content validation. The SR-MAD has been modified to meet the needs of PMR Studies 2065-1A and 2065-4B, and has been renamed the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ).

This study will seek to further develop and validate the POMAQ using the the Food and Drug Administration (FDA) Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (FDA 2009) as a reference for conducting qualitative research throughout the process of instrument development to ensure the content validity of a measure and to evaluate the comprehensibility of included questions. This qualitative study to evaluate content validity will be conducted prior to the quantitative study to evaluate construct validity

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: January 18, 2016
• Est. primary completion date: January 18, 2016
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. Patients who, based on the Site Investigator's clinical judgment, have chronic moderate to severe pain

3. Willing to provide written informed consent

4. Able to participate in a one-on-one interview

5. Able to read, speak, and understand English and complete all study assessments.

Exclusion Criteria:

1. Cognitive, psychiatric or other impairment based on the Site Investigator's clinical judgment that would interfere with participating in a one-on-one discussion

2. Terminal illness with life expectancy < 6 months.

Related Conditions & MeSH terms

• Drug Abuse
• Narcotic Abuse
• Opiate Addiction
• Opioid-Related Disorders
• Substance-Related Disorders

Intervention

Other:
• Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)

Locations

Country	Name	City	State
United States	Evidera	Bethesda	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Member Companies of the Opioid PMR Consortium	Evidera

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Content validity of POMAQ	Evidence of content validity from patients regarding the interpretation of POMAQ items, ease of completion, the comprehensiveness of instrument, and the appropriateness of the format, response scales, and recall period	Day 1, based upon survey completed at single visit